Category: Off-label Use / Prescribing
-
Infuse Bone Graft: Medtronic-Funded Studies Essentially Ignored Serious Medical Complications And Side Effects Associated With Its Back Surgery Product
A 2009 – 2012 Series Of Investigative Reports Published By The Milwaukee Journal Sentinel Exposed Various "Problems" With How Medtronic Went About Boosting Sales Of Infuse (Posted by Tom Lamb at DrugInjuryWatch.com) In the…
-
Medtronic Infuse Bone Graft Efficacy And Safety Study By Yale: Widely Anticipated Results Are Set To Be Released In June 2013
This Controversial Medtronic Spine Treatment Was Put In The Spotlight By June 2011 Medical Journal Articles About Serious Risks And Problems With Infuse (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "Medtronic bone graft has…
-
Off-Label Prescribing Of Drugs: An Explanation And Some Practical Guidance For Patients
Don't Be Afraid To Talk With Your Doctor About Any Medication You Are Prescribed — Especially If The Drug Is Being Used As A Treatment NOT Approved By FDA (Posted by Tom Lamb at…
-
FDA Staff Wants Amgen To Add Stronger Warning About Enbrel Side Effects In Children
June 2008 Staff Report Cites Cancers, Infections, And Neurological Problems Similar To Serious Side Effects In Adults (Posted by Tom Lamb at DrugInjuryWatch.com) On June 16, 2008 the FDA released a staff report, "Enbrel…
-
Heart Failure Drug Natrecor Fails Efficacy Part Of “Off-label” Use Study
Safety Profile Of Natrecor Continues To Be Subject Of Controversy And Debate (Posted by Tom Lamb at DrugInjuryWatch.com) The results of a large study for Johnson & Johnson’s heart failure drug Natrecor failed to…
-
FDA Issues March 2007 Safety Alert For Pfizer Antibiotic Zyvox
Study Suggests That Higher Chance Of Death Is Related To The Type Of Organism Causing A Patient’s Infection (Posted by Tom Lamb at DrugInjuryWatch.com) On March 16, 2007 the FDA issued a safety alert…
-
Procrit, Epogen, And Aranesp: New “Black Box” Warnings Only First Part Of FDA’s Safety Re-evaluation
Popular Anemia Drugs Have Increased Risk Of Death, Blood Clots, Strokes, And Heart Attacks, Especially In Context Of Off-label Prescribing And Use (Posted by Tom Lamb at DrugInjuryWatch.com) On March 9, 2007 the FDA…
-
Natrecor: An Example Of How Drug Companies Might Influence Doctors
"Off-label" Prescribing Is At Center Of Ongoing Natrecor Controversy A recent article of interest is "The Rise And Fall Of Natrecor For Congestive Heart Failure: Implications For Drug Policy", by Aaron S. Kesselheim, Michael…
-
Natrecor: A Definitive Safety Study Is Long Overdue
Off-label Use Of Natrecor Continues To Be A Problem A year ago two medical journal articles raised serious safety issues about Natrecor; in summary: (1) a 50% increased risk of kidney damage or renal…
-
“Black-box” Warnings Are Forgotten Or Ignored By Some Doctors
The So-called Black Box Is FDA’s Highest Form Of Drug Safety Alert In the February 14, 2006 edition of the medical journal Archives of Internal Medicine there is a report that many patients are…